PKI-179

• CAT Number: I008785
• CAS Number: 1197160-28-3
• Molecular Formula: C25H28N8O3
• Molecular Weight: 488.54
• Purity: ≥95%
• Synonyms: 1-[4-[4-morpholin-4-yl-6-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,3,5-triazin-2-yl]phenyl]-3-pyridin-4-ylurea
• InChI: InChI=1S/C25H28N8O3/c34-25(28-19-7-9-26-10-8-19)27-18-3-1-17(2-4-18)22-29-23(32-11-13-35-14-12-32)31-24(30-22)33-20-5-6-21(33)16-36-15-20/h1-4,7-10,20-21H,5-6,11-16H2,(H2,26,27,28,34)
• InChIKey: WXUUCRLKXQMWRY-UHFFFAOYSA-N
• SMILES: C1CC2COCC1N2C3=NC(=NC(=N3)N4CCOCC4)C5=CC=C(C=C5)NC(=O)NC6=CC=NC=C6

PKI-179 (Cat No.: I008785) is a potent dual inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two central regulators of cell growth, metabolism, and survival. By targeting these pathways, PKI-179 suppresses abnormal signaling associated with cancer and other proliferative disorders. It is widely used in preclinical research to study tumor biology, drug resistance, and apoptotic mechanisms. Although not developed for clinical application, PKI-179 serves as a valuable pharmacological tool in oncology research and drug discovery targeting PI3K/mTOR signaling.

Reference

[1]. Venkatesan AM, et, al. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5869-73.
[Content Brief]

[2]. Rehan M. A structural insight into the inhibitory mechanism of an orally active PI3K/mTOR dual inhibitor, PKI-179 using computational approaches. J Mol Graph Model. 2015 Nov;62:226-234.
[Content Brief]